Status: Recruiting
Strategy for Improving Stroke Treatment Response
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Participants needed: 300
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Translational Sciences, Inc.Updated: Jun 2, 2026Locations: 52
Eligibility criteria
Age 18 years and older [+7]
Received endovascular treatment with clot engagement. [+28]